{"title":"Ironwood制药公司通过Bionomics交易扩大了利那克洛肽以外的产品线","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I2.1675","DOIUrl":null,"url":null,"abstract":"In order to expand its pipeline beyond the late-stage gastrointestinal drug linaclotide, Ironwood Pharmaceuticals has licensed exclusive global rights to develop and commercialise Bionomics’ Phase I anti‐anxiety compound BNC210 and other related compounds. The deal is worth up to US$345 M, including US$3 M upfront and US$10 M in near-term research funding and milestone payments, as well as royalties on sales of resulting products.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ironwood Pharmaceuticals Expands its Pipeline Beyond Linaclotide with Bionomics Deal\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I2.1675\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In order to expand its pipeline beyond the late-stage gastrointestinal drug linaclotide, Ironwood Pharmaceuticals has licensed exclusive global rights to develop and commercialise Bionomics’ Phase I anti‐anxiety compound BNC210 and other related compounds. The deal is worth up to US$345 M, including US$3 M upfront and US$10 M in near-term research funding and milestone payments, as well as royalties on sales of resulting products.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-06-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I2.1675\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I2.1675","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ironwood Pharmaceuticals Expands its Pipeline Beyond Linaclotide with Bionomics Deal
In order to expand its pipeline beyond the late-stage gastrointestinal drug linaclotide, Ironwood Pharmaceuticals has licensed exclusive global rights to develop and commercialise Bionomics’ Phase I anti‐anxiety compound BNC210 and other related compounds. The deal is worth up to US$345 M, including US$3 M upfront and US$10 M in near-term research funding and milestone payments, as well as royalties on sales of resulting products.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
